Fluorescent labeled product MFPs-1-FITC for treating alcoholic liver injury as well as preparation method and application of fluorescent labeled product MFPs-1-FITC
By combining mulberry polysaccharide with fluorescein isothiocyanate, the fluorescent labeled product MFPs-1-FITC was prepared, which solved the problem of pharmacokinetic research on polysaccharides in vivo, improved bioavailability, and in alcoholic liver injury model showed significant therapeutic effects.
Patent Information
- Application Number
- CN202410966794.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively detect and study the pharmacokinetic characteristics of natural polysaccharides in the body, especially because the polysaccharide lacks light absorbing groups and chromogenic groups, which cannot be directly detected by ultraviolet and fluorescence detectors, and the endogenous properties in the organisms are Polysaccharides interfere with the determination of exogenous polysaccharides, resulting in low bioavailability.
Mulberry polysaccharide combined with fluorescein isothiocyanate (FITC) to prepare the fluorescent labeled product MFPs-1-FITC. By measuring its fluorescence intensity in rats, its pharmacokinetic characteristics are explored, thereby improving the Bioavailability and detection efficiency of polysaccharides.
Quantitative analysis of polysaccharides was achieved, bioavailability was improved, and a long half-life and significant liver concentration were shown in the alcoholic liver injury model, indicating that it has protective effects on the liver and has certain intestinal diseases. therapeutic effect.
Smart Images

Figure CN118978608A_ABST
Abstract
Description
Technical field:
[0001] The invention relates to a fluorescent labeling product MFPs-1-FITC for treating alcoholic liver damage and a preparation method and application thereof, belonging to the field of medical technology. Technical background:
[0002] Mulberry (Fructus Mori), derived from the mature fruit of the mulberry tree (Morus alba L.) of the Moraceae family, is not only a traditional Chinese medicinal material, but also rich in a variety of nutrients and bioactive substances. In particular, mulberry polysaccharides, as one of its main active ingredients, have been proven to have multiple pharmacological effects such as immunomodulation, hypoglycemic, anti-oxidation, anti-fatigue, and liver protection.
[0003] Natural polysaccharides have attracted extensive attention from the functional food and biopharmaceutical industries due to their wide range of biological activities, safety and low toxicity. Elucidating the pharmacokinetic information of polysaccharides in vivo can better understand the pharmacological mechanism of polysaccharides; evaluating the pharmacokinetics of polysaccharides in vivo is a necessary step for the application of polysaccharides in drugs and health products, so it is very necessary to measure the pharmacokinetic parameters of polysaccharides in vivo. In recent years, the pharmacokinetic research of polysaccharides has been very slow, mainly for the following three reasons: 1. Polysaccharides lack absorbing groups and chromophores and cannot be directly detected by ultraviolet and fluorescence detectors; 2. The presence of endogenous polysaccharides in organisms will interfere with the determination of exogenous polysaccharides; 3. Polysaccharides are polymers, and even purified polysaccharides only have a certain range of molecular weights. Therefore, combining the physicochemical properties of polysaccharides and developing new microanalysis techniques is one of the important directions of their pharmacokinetic research.
[0004] In addition, due to the large molecular weight, charge and other physical and chemical properties of polysaccharides, they have disadvantages such as low bioavailability and difficulty in absorption after oral administration.
[0005] Therefore, in order to effectively detect polysaccharide components in pharmacokinetic studies and improve the bioavailability of polysaccharides after oral administration, the present invention combines polysaccharides with fluorescein isothiocyanate (FITC). The obtained fluorescently labeled product can not only effectively detect polysaccharide components in pharmacokinetic studies, but also improve the bioavailability of polysaccharides. Summary of the invention:
[0006] The technical problem to be solved by the present invention is to provide a fluorescently labeled product MFPs-1-FITC for treating alcoholic liver injury, and a preparation method and application thereof. By measuring the fluorescence intensity of the fluorescently labeled product MFPs-1-FITC in rats, the concentration of MFPs-1 is indirectly reflected, thereby exploring its pharmacokinetic characteristics in vivo, and further determining that MFPs-1-FITC can effectively treat alcoholic liver injury.
[0007] In order to solve the above technical problems, the present invention adopts the following technical scheme: a fluorescent labeled product MFPs-1-FITC for treating alcoholic liver damage, wherein the fluorescent labeled product MFPs-1-FITC is prepared by first separating and purifying mulberry fruit to obtain fluorescent polysaccharide MFPs-1, reacting the fluorescent polysaccharide MFPs-1 with 4-hydroxyphenylethylamine to obtain MFPs-1-Tyr, and then synthesizing MFPs-1-Tyr with fluorescein isothiocyanate.
[0008] The aforementioned preparation method is carried out according to the following steps:
[0009] (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 30-60 mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1g:2-4mL, each time for 1.5-2.5h, defatting 2-4 times, discarding the petroleum ether layer, obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 80-100°C, the ratio of mulberry sample to distilled water is 1g:2-4mL, each time for 1.5-2.5h, extracting 2-4 times, filtering, combining the filtrate, centrifuging the filtrate at 3500rpm for 5-15min, concentrating the supernatant, and obtaining a mulberry polysaccharide extract;
[0010] (2) adding 2.5%-3.5% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution is 0.5-1.5:0.5-1.5, standing at 4°C for 3-5 hours, centrifuging at 3000-4000 r / min for 5-15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 2.5%-3.5% trichloroacetic acid solution, the mass ratio of the concentrate to 3% trichloroacetic acid solution is 0.5-1.5:0.5-1.5, standing at 4°C for 3-5 hours, centrifuging at 3000-4000 r / min for 5-15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution;
[0011] (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 40-60%, placing the solution at 3-5°C for 22-26 hours, centrifuging at 3500 r / min for 5-15 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP;
[0012] (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 200-400 mL of distilled water, collect 20-40 tubes of eluate, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, concentrate, dialyze the concentrate with a 3500Da dialysis bag, and vacuum freeze-dry the dialyzate to obtain the fluorescent polysaccharide MFPs-1;
[0013] (5) Synthesis of MFPs-1-Tyr: 300-500 mg of fluorescent polysaccharide MFPs-1 was dissolved in 10-20 mL of 0.2 mol / L phosphate buffer at pH 8.0, 300-500 mg of Tyr and 100.00-200.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 90-100 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex Elution was performed through a G-100 column with 200-400 mL of distilled water, and 20-40 tubes of eluate were collected, with 10 mL in each tube. The sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry. The eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined and dialyzed with a 3500 Da dialysis bag and then freeze-dried to obtain MFPs-1-Tyr;
[0014] (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water, and the pH was adjusted to 8-9 with 0.5 mol / L Na2CO3, 40-60 mg of fluorescein isothiocyanate was added, and the mixture was reacted in the dark at room temperature for 10-14 h, and then 2-4 volumes of anhydrous ethanol were added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved in water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500 Da dialysis bag, and the dialyzate was passed through Sephadex The product was eluted and purified using a G-100 column with 200-400 mL of distilled water, and 20-40 tubes of eluate were collected, with 10 mL in each tube. The sugar content was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was taken for detection, and the fluorescence intensity was determined by fluorescence spectroscopy analysis with an excitation wavelength of 492 nm and an emission wavelength of 518 nm. The eluate with fluorescence absorption at 490 nm was collected, combined, and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
[0015] Specifically, the above preparation method is carried out according to the following steps:
[0016] (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 40-mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1 g:3 mL, each time for 2 hours, defatting 3 times, discarding the petroleum ether layer, obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 90° C., the ratio of mulberry sample to distilled water is 1 g:3 mL, each time for 2 hours, extracting 3 times, filtering, combining the filtrate, centrifuging the filtrate at 3500 rpm for 10 minutes, and concentrating the supernatant to obtain a mulberry polysaccharide extract;
[0017] (2) adding 3% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 3% trichloroacetic acid solution, the mass ratio of mulberry concentrate to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution;
[0018] (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 50%, placing it at 4°C for 24 hours, centrifuging it at 3500 r / min for 10 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP;
[0019] (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 300 mL of distilled water, collect 30 tubes of eluate, collect 10 mL of eluate in each tube, and track and determine the sugar content of each tube of eluate using the phenol-sulfuric acid method until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, and concentrate. The concentrate is dialyzed with a 3500Da dialysis bag, and the dialyzate is vacuum freeze-dried to obtain MFPs-1;
[0020] (5) Synthesis of MFPs-1-Tyr: 400 mg of MFPs-1 was dissolved in 15 mL of 0.2 mol / L phosphate buffer at pH 8.0, 400 mg of Tyr and 150.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 96 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex. Elution was performed through a G-100 column with 300 mL of distilled water, and 30 tubes of eluate were collected, with 10 mL in each tube. The sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry. The eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined and dialyzed with a 3500 Da dialysis bag and then freeze-dried to obtain MFPs-1-Tyr.
[0021] (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water, and the pH was adjusted to 8.5 with 0.5 mol / L Na2CO3, 50 mg of fluorescein isothiocyanate was added, and the reaction was carried out in the dark at room temperature for 12 h, and then 3 volumes of anhydrous ethanol were added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved in water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500 Da dialysis bag, and the dialyzate was passed through Sephadex The product was eluted and purified using a G-100 column with 300 mL of distilled water, and 30 tubes of eluate were collected, with 10 mL in each tube. The sugar content was determined using the phenol-sulfuric acid method, and the sugar-containing eluate was collected. The fluorescence intensity was determined by fluorescence spectroscopy with an excitation wavelength of 492 nm and an emission wavelength of 518 nm. The eluate with fluorescence absorption at 490 nm was collected and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
[0022] The application of the fluorescently labeled product MFPs-1-FITC for treating alcoholic liver injury in biological detection, the biological detection method of the fluorescently labeled product MFPs-1-FITC is carried out according to the following steps:
[0023] (1) diluting MFPs-1-FITC with water to prepare a 100-200 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 100-200 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0024] (2) Preparation of plasma samples: blood was collected from the orbits of rat biological samples and collected into anticoagulant tubes. The blood samples were centrifuged at 3000-5000 r / min for 5-15 min at 3-5°C to separate the plasma. 100-150 μL of plasma was taken, 100-150 μL of PBS solution was added, vortexed and mixed, and centrifuged at 4000-6000 r / min for 5-15 min to obtain the supernatant to obtain the plasma sample.
[0025] (3) Preparation of tissue samples: Collect rat biological sample organ tissues, wash with physiological saline and dry the surface moisture, accurately weigh the organ tissues, add PBS solution, the mass ratio of organ tissue to PBS solution is 1:8-10, use a homogenizer to homogenize the tissues, centrifuge at 10000-14000 r / min for 5-15 min, take the supernatant and obtain the tissue sample;
[0026] The rat organ tissues include stomach, large intestine, small intestine, liver, spleen, lung and kidney;
[0027] (4) Preparation of urine samples: Take rat biological sample urine, centrifuge at 3000-5000 r / min for 5-15 min, filter and take 30-50 μL of supernatant, filter through a microporous filter, add 150-250 μL of PBS solution, vortex mix, centrifuge at 10000-14000 r / min for 5-15 min, take the supernatant, and obtain a urine sample;
[0028] (5) Preparation of fecal samples: Rat biological sample feces was dried to constant weight, and then added with PBS solution, with the mass ratio of feces to PBS solution being 1:8-10. After mixing, the mixture was vortexed for 5-15 min, allowed to stand for 5-15 min, and centrifuged at 10000-14000 r / min for 5-15 min. The supernatant was collected to obtain a fecal sample.
[0029] (6) Fluorescence intensity detection: Plasma samples, tissue samples, urine samples and feces samples were taken respectively, and PBS solution was used as blank control for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader.
[0030] In the aforementioned step (1), MFPs-1-FITC is diluted with water to prepare a 150 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution is administered to rats by gavage, with the gavage dose being 150 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample.
[0031] In the above step (2), the preparation of plasma samples: blood is collected from the eye sockets of rat biological samples, and the blood samples are collected in anticoagulant tubes. The blood samples are centrifuged at 4000 r / min for 10 min at 4°C to separate the plasma. 120 μL of plasma is taken, 120 μL of PBS solution is added, the mixture is vortexed and mixed, and the mixture is centrifuged at 5000 r / min for 10 min to obtain the supernatant to obtain the plasma sample.
[0032] In the above step (3), the preparation of tissue samples: collecting rat biological sample organ tissues, washing with physiological saline and drying the surface moisture, accurately weighing the organ tissues, adding PBS solution, the mass ratio of organ tissue to PBS solution is 1:9, using a homogenizer to homogenize the tissues, centrifuging at 12000r / min for 10min, taking the supernatant, and obtaining the tissue sample;
[0033] The rat organ tissues include stomach, large intestine, small intestine, liver, spleen, lung and kidney.
[0034] In the above step (4), the urine sample is prepared by taking the rat biological sample urine, centrifuging at 4000 r / min for 10 min, filtering and taking 40 μL of the supernatant, filtering with a microporous filter membrane, adding 200 μL of PBS solution, vortex mixing, centrifuging at 12000 r / min for 10 min, taking the supernatant, and obtaining a urine sample.
[0035] In the above step (5), the feces sample was prepared by drying the feces of the rat biological sample to a constant weight, adding PBS solution, the mass ratio of feces to PBS solution being 1:9, mixing, vortexing for 10 min, standing for 10 min, centrifuging at 12000 r / min for 10 min, and taking the supernatant to obtain a feces sample.
[0036] Compared with the prior art, the present invention has the following beneficial effects:
[0037] 1. After the fluorescent polysaccharide MFPs-1 is prepared into MFPs-1-FITC, the polysaccharide in rat biological samples can be quantitatively analyzed by a multifunctional microplate reader. According to methodological investigation, the method has a good linear relationship in the range of 0.3μg / mL to 30μg / mL. The RSD of intra-day precision and inter-day precision both meet the test requirements (RSD≤10.94%). The results of the stability investigation show that the plasma, tissue and excrement samples containing MFPs-1-FITC have good stability under different conditions.
[0038] 2. The fluorescence intensity of rat plasma, organ tissues and excreta after rats were gavaged with MFPs-1-FITC was measured by using a multifunctional microplate reader. The results showed that the content of MFPs-1-FITC in rat plasma reached a peak at 0.5h. DAS2.0 software was used for intelligent analysis, and the results showed that MFPs-1-FITC showed a two-compartment model in rats. Tissue distribution showed that MFPs-1-FITC could be detected in all tissues and organs except heart and brain tissues, and its content in the gastrointestinal tract was high and existed for a long time.
[0039] 3. After the fluorescent polysaccharide MFPs-1 was prepared into MFPs-1-FITC, its half-life in the rats of the alcoholic liver injury model group increased, indicating that MFPs-1 existed in the rats of the alcoholic liver injury model group for a long time, and the concentration of MFPs-1-FITC in the rats of the alcoholic liver injury model group was higher than that in the liver of normal rats. The liver is the first barrier to the absorption of exogenous substances. The concentration of MFPs-1-FITC in the liver reflects the absorption level of MFPs-1-FITC. Compared with the plasma concentration, the concentration of MFPs-1-FITC in the liver increased significantly and lasted for a long time, indicating that MFPs-1-FITC can be absorbed by the circulatory system and has a certain protective effect on the liver. MFPs-1-FITC has a therapeutic effect on alcoholic liver injury.
[0040] 4. In addition, MFPs-1-FITC stays in the intestine for a long time, indicating that MFPs-1-FITC also has a certain therapeutic effect on intestinal diseases. Description of the drawings:
[0041] Figure 1 : UV-visible spectra ((A) is the elution curve of MFPs-1-Tyr; (B) is the elution curve of MFPs-1-FITC; (C) is the UV-visible spectra of MFPs-1, FITC, MFPs-1-Tyr, and MFPs-1-FITC);
[0042] Figure 2 : Standard curve of FITC;
[0043] Figure 3 : Drug-time curve of MFPs-1-FITC after intragastric administration to rats;
[0044] Figure 4 : Curve of cumulative excretion of MFPs-1-FITC in urine and feces within 24 hours after oral administration of MFPs-1-FITC in rats;
[0045] Figure 5: The cumulative excretion of MFPs-1-FITC in urine and feces within 24 hours after oral administration of rats was as a percentage of the administered dose. Specific implementation method:
[0046] The present invention is further described below in conjunction with the examples, but is not intended to be limiting of the present invention. The PBS solutions used in the following examples are all phosphate buffer solutions with a pH of 7.2 to 7.4.
[0047] Implementation 1:
[0048] Preparation process of fluorescent labeling product MFPs-1-FITC:
[0049] (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 40-mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1 g:3 mL, each time for 2 hours, defatting 3 times, discarding the petroleum ether layer, obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 90° C., the ratio of mulberry sample to distilled water is 1 g:3 mL, each time for 2 hours, extracting 3 times, filtering, combining the filtrate, centrifuging the filtrate at 3500 rpm for 10 minutes, and concentrating the supernatant to obtain a mulberry polysaccharide extract;
[0050] (2) adding 3% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 3% trichloroacetic acid solution, the mass ratio of mulberry concentrate to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution;
[0051] (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 50%, placing it at 4°C for 24 hours, centrifuging it at 3500 r / min for 10 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP;
[0052] (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 300 mL of distilled water, collect 30 tubes of eluate, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, and concentrate. The concentrate is dialyzed with a 3500Da dialysis bag, and the dialyzate is vacuum freeze-dried to obtain the fluorescent polysaccharide MFPs-1;
[0053] (5) Synthesis of MFPs-1-Tyr: 400 mg of fluorescent polysaccharide MFPs-1 was dissolved in 15 mL of 0.2 mol / L phosphate buffer at pH 8.0, 400 mg of Tyr and 150.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 96 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex. Elution was performed through a G-100 column with 300 mL of distilled water, and 30 tubes of eluate were collected, with 10 mL in each tube. The sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry. The eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined and dialyzed with a 3500 Da dialysis bag and then freeze-dried to obtain MFPs-1-Tyr.
[0054] (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water, and the pH was adjusted to 8.5 with 0.5 mol / L Na2CO3, 50 mg of fluorescein isothiocyanate was added, and the mixture was allowed to react at room temperature in the dark for 12 h, and then 3 volumes of anhydrous ethanol were added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved in water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500 Da dialysis bag, and the dialysate was passed through Sephadex The product was eluted and purified using a G-100 column with 300 mL of distilled water, and 30 tubes of eluate were collected, with 10 mL in each tube. The sugar content was determined using the phenol-sulfuric acid method, and the sugar-containing eluate was collected. The fluorescence intensity was determined by fluorescence spectroscopy with an excitation wavelength of 492 nm and an emission wavelength of 518 nm. The eluate with fluorescence absorption at 490 nm was collected and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
[0055] Embodiment 2:
[0056] Preparation process of fluorescent labeling product MFPs-1-FITC:
[0057] (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 60-mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1 g: 4 mL, each time for 2.5 hours, defatting 4 times, discarding the petroleum ether layer, and obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 100° C., the ratio of mulberry sample to distilled water is 1 g: 4 mL, each time for 2.5 hours, extracting 4 times, filtering, combining the filtrate, centrifuging the filtrate at 3500 rpm for 15 minutes, and concentrating the supernatant to obtain a mulberry polysaccharide extract;
[0058] (2) adding 3.5% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution being 1.5:0.5, standing at 4°C for 5 hours, centrifuging at 4000 r / min for 15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 3.5% trichloroacetic acid solution, the mass ratio of mulberry concentrate to 3% trichloroacetic acid solution being 1.5:0.5, standing at 4°C for 5 hours, centrifuging at 4000 r / min for 15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution;
[0059] (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 60%, placing it at 5°C for 26 hours, centrifuging it at 3500 r / min for 15 minutes, collecting the precipitate, washing the precipitate with anhydrous ethanol for 3 times, and vacuum freeze-drying to obtain mulberry polysaccharide MFP;
[0060] (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 400 mL of distilled water, collect 40 tubes, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide. Collect the sugar-containing eluate with an absorption peak at 490 nm, combine, and concentrate. The concentrate is dialyzed with a 3500Da dialysis bag, and the dialyzate is vacuum freeze-dried to obtain the fluorescent polysaccharide MFPs-1;
[0061] (5) Synthesis of MFPs-1-Tyr: 500 mg of fluorescent polysaccharide MFPs-1 was dissolved in 20 mL of 0.2 mol / L phosphate buffer at pH 8.0, 500 mg of Tyr and 200.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 100 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex Elution was performed through a G-100 column with 400 mL of distilled water, and 40 tubes of eluate were collected, with 10 mL in each tube; the sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry, and the eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined and dialyzed with a 3500 Da dialysis bag and then freeze-dried to obtain MFPs-1-Tyr;
[0062] (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water, and the pH was adjusted to 9 with 0.5 mol / L Na2CO3, 60 mg of fluorescein isothiocyanate was added, and the mixture was reacted in the dark at room temperature for 14 h, and then 4 volumes of anhydrous ethanol were added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved in water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500 Da dialysis bag, and the dialysate was passed through Sephadex The product was eluted and purified using a G-100 column with 400 mL of distilled water. 40 tubes of eluate were collected, with 10 mL in each tube. The sugar content was determined using the phenol-sulfuric acid method. The sugar-containing eluate was collected and the fluorescence intensity was determined by fluorescence spectroscopy analysis with an excitation wavelength of 492 nm and an emission wavelength of 518 nm. The eluate with fluorescence absorption at 490 nm was collected, combined, and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
[0063] Embodiment 3:
[0064] Preparation process of fluorescent labeling product MFPs-1-FITC:
[0065] (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 30-mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1 g: 2 mL, each time for 1.5 hours, defatting twice, discarding the petroleum ether layer, and obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 80° C., the ratio of mulberry sample to distilled water is 1 g: 2 mL, each time for 1.5 hours, extracting twice, filtering, combining the filtrate, centrifuging the filtrate at 3500 rpm for 5 minutes, and concentrating the supernatant to obtain a mulberry polysaccharide extract;
[0066] (2) adding 2.5% trichloroacetic acid solution to the mulberry polysaccharide extract, the mass ratio of the mulberry polysaccharide extract to the 3% trichloroacetic acid solution being 0.5:1.5, standing at 4°C for 3 hours, centrifuging at 3000 r / min for 5 minutes, collecting the supernatant, concentrating the supernatant using a rotary evaporator, taking the concentrate and adding 2.5% trichloroacetic acid solution, the mass ratio of the concentrate to the 3% trichloroacetic acid solution being 0.5:1.5, standing at 4°C for 3 hours, centrifuging at 3000 r / min for 5 minutes, collecting the supernatant, concentrating the supernatant using a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution;
[0067] (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 40%, placing it at 3°C for 22 hours, centrifuging it at 3500 r / min for 5 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP;
[0068] (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 200 mL of distilled water, collect 20 tubes, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, and concentrate. The concentrate is dialyzed with a 3500Da dialysis bag, and the dialyzate is vacuum freeze-dried to obtain the fluorescent polysaccharide MFPs-1;
[0069] (5) Synthesis of MFPs-1-Tyr: 300 mg of fluorescent polysaccharide MFPs-1 was dissolved in 10 mL of 0.2 mol / L phosphate buffer at pH 8.0, 300-500 mg of Tyr and 100.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 90 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex Elution was performed through a G-100 column with 200 mL of distilled water, and 20 tubes of eluate were collected, with 10 mL in each tube; the sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry, and the eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined and dialyzed with a 3500 Da dialysis bag and then freeze-dried to obtain MFPs-1-Tyr;
[0070] (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water, and the pH was adjusted to 8 using 0.5 mol / L Na2CO3. 40 mg of fluorescein isothiocyanate was added. After reacting at room temperature in the dark for 10 h, 2 volumes of anhydrous ethanol were added to produce a yellow-green precipitate. The precipitate was separated by centrifugation, and the precipitate was redissolved in water and precipitated with anhydrous ethanol. The redissolution-precipitation process was repeated three times. After the precipitate was dissolved, it was dialyzed using a 3500 Da dialysis bag, and the dialyzate was passed through Sephadex The product was eluted and purified using a G-100 column with 200 mL of distilled water. 20 tubes of eluate were collected, with 10 mL in each tube. The sugar content was determined using the phenol-sulfuric acid method. The sugar-containing eluate was collected and the fluorescence intensity was determined by fluorescence spectroscopy analysis with an excitation wavelength of 492 nm and an emission wavelength of 518 nm. The eluate with fluorescence absorption at 490 nm was collected, combined, and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
[0071] Embodiment 4:
[0072] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0073] (1) diluting MFPs-1-FITC with water to prepare a 150 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 150 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0074] (2) Preparation of plasma samples: Blood samples were collected from the orbits of rats and placed in anticoagulant tubes. The samples were centrifuged at 4000 r / min for 10 min at 4°C to separate the plasma. 120 μL of plasma was taken and 120 μL of PBS solution was added. The mixture was vortexed and centrifuged at 5000 r / min for 10 min. The supernatant was taken to obtain the plasma sample.
[0075] (3) Preparation of tissue samples: The stomach, large intestine, small intestine, liver, spleen, lung and kidney tissues of rat biological samples were collected respectively, washed with physiological saline and the surface moisture was dried, each organ tissue was accurately weighed, and PBS solution was added. The mass ratio of each organ tissue to PBS solution was 1:9. The tissues were homogenized using a homogenizer and centrifuged at 12000 r / min for 10 min. The supernatant was collected to obtain stomach, large intestine, small intestine, liver, spleen, lung and kidney tissue samples respectively;
[0076] (4) Preparation of urine samples: Rat biological sample urine was centrifuged at 4000 r / min for 10 min, 40 μL of supernatant was filtered, and after filtering with a microporous filter, 200 μL of PBS solution was added, vortexed and mixed, and centrifuged at 12000 r / min for 10 min, and the supernatant was obtained to obtain a urine sample;
[0077] (5) Preparation of fecal samples: Preparation of fecal samples: Rat biological sample feces was dried to constant weight, and PBS solution was added, with the mass ratio of feces to PBS solution being 1:9. After mixing, the mixture was vortexed for 10 min, allowed to stand for 10 min, and centrifuged at 12000 r / min for 10 min. The supernatant was collected to obtain a fecal sample.
[0078] (6) Fluorescence intensity detection: plasma samples, gastric tissue samples, large intestine tissue samples, small intestine tissue samples, liver tissue samples, spleen tissue samples, lung tissue samples, kidney tissue samples, urine samples and feces samples were taken, and PBS solution was used as a blank control for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader. The fluorescence intensity of the plasma samples, gastric tissue samples, large intestine tissue samples, small intestine tissue samples, liver tissue samples, spleen tissue samples, lung tissue samples, kidney tissue samples, urine samples and feces samples was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of each sample.
[0079] Embodiment 5:
[0080] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0081] (1) MFPs-1-FITC was diluted with water to prepare a 200 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution was administered to rats by intragastric administration, with the intragastric dose being 200 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0082] (2) Preparation of plasma samples: Blood samples were collected from the orbits of rats and placed in anticoagulant tubes. The samples were centrifuged at 5000 r / min for 15 min at 5°C to separate the plasma. 150 μL of plasma was taken and 150 μL of PBS solution was added. The mixture was vortexed and centrifuged at 6000 r / min for 15 min. The supernatant was taken to obtain the plasma sample.
[0083] (3) Fluorescence intensity detection: Take a plasma sample and use PBS solution as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex is 492 nm, the fluorescence emission wavelength Em is 518 nm, and the instrument is a multifunctional microplate reader. The fluorescence intensity of the plasma sample is subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the plasma sample.
[0084] Embodiment 6:
[0085] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0086] (1) diluting MFPs-1-FITC with water to prepare a 180 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 180 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0087] (2) Preparation of tissue samples: Gastric tissue of rat biological samples was collected, washed with physiological saline, and the surface moisture was dried. The gastric tissue was accurately weighed, and PBS solution was added. The mass ratio of gastric tissue to PBS solution was 1:10. The tissue was homogenized using a homogenizer, centrifuged at 14000 r / min for 15 min, and the supernatant was collected to obtain a gastric tissue sample;
[0088] (3) Fluorescence intensity detection: Gastric tissue samples were taken and PBS solution was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader. The fluorescence intensity of the gastric tissue sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the gastric tissue sample.
[0089] Embodiment 7:
[0090] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0091] (1) diluting MFPs-1-FITC with water to prepare a 180 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 180 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0092] (2) Preparation of urine samples: Rat biological sample urine was centrifuged at 5000 r / min for 15 min, 50 μL of supernatant was filtered, and after filtering with a microporous filter membrane, 250 μL of PBS solution was added, vortexed and mixed, and centrifuged at 14000 r / min for 15 min, and the supernatant was obtained to obtain a urine sample;
[0093] (2) Preparation of fecal samples: Rat feces were dried to constant weight, and then added with PBS solution at a mass ratio of feces to PBS solution of 1:10. After mixing, the mixture was vortexed for 15 min, allowed to stand for 15 min, and centrifuged at 14,000 rpm for 15 min. The supernatant was collected to obtain a fecal sample.
[0094] (3) Fluorescence intensity detection: Urine samples and feces samples were taken, and PBS solution was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, and the fluorescence emission wavelength Em was 518 nm. The instrument was a multifunctional microplate reader. The fluorescence intensity of the urine sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the urine sample.
[0095] Embodiment 8:
[0096] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0097] (1) diluting MFPs-1-FITC with water to prepare a 180 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 180 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0098] (2) Preparation of fecal samples: Rat feces were dried to constant weight, and then added with PBS solution at a mass ratio of feces to PBS solution of 1:10. After mixing, the mixture was vortexed for 15 min, allowed to stand for 15 min, and centrifuged at 14,000 rpm for 15 min. The supernatant was collected to obtain a fecal sample.
[0099] (3) Fluorescence intensity detection: Fecal samples were taken and PBS solution was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader. The fluorescence intensity of the fecal sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the fecal sample.
[0100] Embodiment 9:
[0101] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0102] (1) MFPs-1-FITC was diluted with water to prepare a 100 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution was administered to rats by intragastric administration, with the intragastric dose being 100 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0103] (2) Preparation of plasma samples: blood samples were collected from the eye sockets of rat biological samples and collected into anticoagulant tubes. The blood samples were centrifuged at 3000-5000 r / min for 5 min at 3°C to separate the plasma. 100 μL of plasma was taken and 100 μL of PBS solution was added. The mixture was vortexed and centrifuged at 4000 r / min for 5 min. The supernatant was taken to obtain the plasma sample.
[0104] (3) Fluorescence intensity detection: Take a plasma sample and use PBS solution as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex is 492 nm, the fluorescence emission wavelength Em is 518 nm, and the instrument is a multifunctional microplate reader. The fluorescence intensity of the plasma sample is subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the plasma sample.
[0105] Embodiment 10:
[0106] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0107] (1) MFPs-1-FITC was diluted with water to prepare a 100 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution was administered to rats by intragastric administration, with the intragastric dose being 100 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0108] (2) Preparation of tissue samples: The liver tissue of the rat biological sample was collected, washed with physiological saline, and the surface moisture was dried. The liver tissue was accurately weighed, and PBS solution was added. The mass ratio of liver tissue to PBS solution was 1:8. The liver tissue was homogenized using a homogenizer, centrifuged at 10,000 r / min for 5 min, and the supernatant was collected to obtain a liver tissue sample;
[0109] (3) Fluorescence intensity detection: A liver tissue sample was taken and a phosphate buffered saline solution with a pH of 7.2-7.4 was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, and the fluorescence emission wavelength Em was 518 nm. The instrument was a multifunctional microplate reader. The fluorescence intensity of the liver tissue sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the liver tissue sample.
[0110] Embodiment 11:
[0111] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0112] (1) MFPs-1-FITC was diluted with water to prepare a 100 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution was administered to rats by intragastric administration, with the intragastric dose being 100 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0113] (2) Preparation of urine samples: Rat biological sample urine was centrifuged at 3000 r / min for 5 min, 30 μL of supernatant was filtered, 150 μL of PBS solution was added after filtering through a microporous filter membrane, vortexed and mixed, and centrifuged at 10000 r / min for 5 min. The supernatant was obtained to obtain a urine sample;
[0114] (3) Fluorescence intensity detection: A urine sample was taken and the PBS solution was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader. The fluorescence intensity of the urine sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the urine sample.
[0115] Embodiment 12:
[0116] Biological detection method of fluorescent labeled product MFPs-1-FITC:
[0117] (1) MFPs-1-FITC was diluted with water to prepare a 100 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution was administered to rats by intragastric administration, with the intragastric dose being 100 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample;
[0118] (2) Preparation of fecal samples: Rat feces were dried to constant weight, and then added with PBS solution at a mass ratio of feces to PBS solution of 1:8. After mixing, the mixture was vortexed for 5 min, allowed to stand for 5 min, and centrifuged at 10,000 rpm for 5 min. The supernatant was collected to obtain a fecal sample.
[0119] (3) Fluorescence intensity detection: Fecal samples were taken and PBS solution was used as a blank control sample for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, the fluorescence emission wavelength Em was 518 nm, and the instrument was a multifunctional microplate reader. The fluorescence intensity of the fecal sample was subtracted from the measured fluorescence intensity of the blank control to obtain the fluorescence intensity of the fecal sample.
[0120] The present invention has carried out a lot of experimental studies, and the following are the results of the experimental studies of the present invention:
[0121] 1 Preparation and characterization of fluorescent polysaccharide MFPs-1 fluorescent labeling products
[0122] 1.1 Experimental materials and drugs
[0123] Source of medicinal materials: Dried mulberry, used as Chinese medicinal materials, was purchased from the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and originated from Sichuan Boren Pharmaceutical Company. Product batch number: 210901. The main reagents are shown in Table 1.
[0124] Table 1 Main reagents involved in the experiment
[0125]
[0126] The main experimental instruments: CNC constant temperature water bath, CNC constant temperature water bath, one-tenth of a balance, one-hundred-thousandth of a balance, vacuum freeze dryer, light absorption microplate reader, Chinese medicine grinder, pure water / ultrapure water system, multi-function microplate reader, etc.
[0127] 1.2 Experimental methods
[0128] 1.2.1 Extraction and purification of fluorescent polysaccharide MFPs-1
[0129] The dried mulberry fruit was dried to constant weight, crushed into powder by a grinder, passed through a 40-mesh sieve, and defatted with petroleum ether (mulberry fruit: petroleum ether = 1:3, W / V), each time for 2 hours, and defatted 3 times; after defatting, the mulberry sample was extracted with distilled water at 90°C (1:3, W / V), each time for 2 hours, and extracted 3 times. After the filtrate was combined, the filtrate was centrifuged (3500rpm, 10min), and the supernatant was concentrated to obtain the mulberry polysaccharide extract. The trichloroacetic acid method was used for deproteinization. The mulberry polysaccharide extract was added with 3% trichloroacetic acid solution at a mass ratio of 1:1, and after standing at 4°C for 4 hours, it was centrifuged at 3500r / min for 10 minutes, the supernatant was collected, and the supernatant was concentrated by a rotary evaporator. This operation was repeated twice to obtain the deproteinized mulberry polysaccharide solution. A certain amount of anhydrous ethanol was added to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reached 50%, and the solution was placed at 4°C for 24 hours, centrifuged (3500r / min, 10min), and the precipitate was collected, washed with anhydrous ethanol for 3 times, and vacuum freeze-dried to obtain mulberry polysaccharide MFP. In order to further purify mulberry polysaccharide and obtain fluorescent polysaccharide MFPs-1, mulberry polysaccharide MFP was purified using a DEAE-52 cellulose column, eluted with 300mL of distilled water, and 10mL of eluate was collected in each tube. 30 tubes were collected, and each tube of eluate was tracked and measured using the phenol-sulfuric acid method until there was no polysaccharide, and the collected peaks (absorption peak at 490nm) were combined, concentrated, dialyzed, and vacuum freeze-dried to obtain MFPs-1.
[0130] Phenol-sulfuric acid method: Preparation of phenol (6%) solution: Accurately weigh 6.00g of phenol, distilled water into a 100mL volumetric flask, shake well, and set aside. Take 0.5mL of eluent, add 0.3mL of 6% phenol solution and 1.5mL of concentrated sulfuric acid in sequence, shake well, place in a boiling water bath and heat for 30min, cool to room temperature, and detect the absorbance A490 at 490nm. By fluorescence detection, the sugar-containing solvent has a fluorescent reaction at 490nm.
[0131] 1.2.2 Synthesis of MFPs-1 fluorescent labeling product MFPs-1-FITC
[0132] (1) Synthesis of MFPs-1-Tyr
[0133] Take 400 mg of MFPs-1, dissolve it in 15 mL of 0.2 mol / L phosphate buffer at pH = 8.0, add 400 mg of Tyr and 150.00 mg of sodium cyanoborohydride, and react in a 37°C water bath for 96 hours. After the reaction is completed, centrifuge, obtain the supernatant, dialyze it with a 3500Da dialysis bag, elute it through a Sephadex G-100 column, elute it with distilled water for a total of 300 mL, and collect 30 tubes of eluate (10 mL per tube). The sugar content in each tube is determined by the phenol-sulfuric acid method, and the sugar-containing eluate is taken, and the elution curve of MFPs-1-Tyr is drawn at 280 nm by ultraviolet-visible spectrophotometry. According to the elution curve, collect the eluate with ultraviolet absorption at 280 nm, dialyze it again with a 3500Da dialysis bag, and freeze-dry it to finally obtain MFPs-1-Tyr.
[0134] (2) Synthesis of MFPs-1-FITC
[0135] MFPs-1-Tyr was dissolved in distilled water and the pH was adjusted to 8.5 using 0.5 mol / L Na2CO3. 50 mg FITC was added and reacted at room temperature in the dark for 12 h. Three volumes of anhydrous ethanol were then added to the solution to produce a yellow-green precipitate. The precipitate was separated by centrifugation, redissolved in water, and precipitated with anhydrous ethanol, and the process was repeated three times. After the precipitate was dissolved, it was dialyzed with a 3500 Da dialysis bag and purified by a Sephadex G-100 column, eluted with 200-400 mL distilled water, and 20-40 tubes of eluate were collected, each tube 10 mL. The sugar content was determined using the phenol-sulfuric acid method, and the fluorescence intensity was determined by fluorescence conditions (excitation wavelength 492 nm, emission wavelength 518 nm). The eluate with fluorescence absorption at 490 nm was collected and freeze-dried to obtain the MFPs-1-FITC product, which was stored in the dark.
[0136] 1.2.3 UV-Vis spectroscopy and fluorescence spectroscopy scanning analysis
[0137] MFPs-1 and its modified products MFPs-1-Tyr, MFPs-1-FITC and FITC were dissolved in water, and UV-visible spectra were measured at 200-800 nm, and fluorescence spectra were analyzed under excitation at 400-550 nm and emission at 450-600 nm.
[0138] 1.2.4 Determination of fluorescence substitution degree of MFPs-1-FITC
[0139] Prepare FITC standard curve: accurately weigh FITC, prepare a 1000 μg / mL stock solution, and dilute it with PBS to different concentrations (2.0 to 0.1 μg / mL). Use PBS as a blank and measure the fluorescence intensity with an ELISA reader at an excitation wavelength of 492 nm and an emission wavelength of 518 nm. Draw a standard curve with FITC concentration as the X-axis and fluorescence intensity as the Y-axis, and calculate its linear regression equation.
[0140] 1.3 Data Statistical Analysis
[0141] The experimental results are expressed as mean ± standard deviation ( All data were statistically analyzed and plotted using Microsoft Excel software.
[0142] 1.4 Results
[0143] 1.4.1 Synthesis of MFPs-1 fluorescent marker MFPs-1-FITC
[0144] Since mulberry polysaccharides contain reducing ends, this study used the reductive amination method for labeling. The aminated polysaccharide (MFPs-1-Tyr) was eluted through a Sephadex G-100 column. Figure 1 As shown in (A), the polysaccharide peak is consistent with the absorption peak of Tyr, and the UV-visible spectrum Figure 1 (C) shows that MFPs-1-Tyr has a significant absorption peak at 280nm, confirming the effective binding of polysaccharide and tyramine. The elution curve of polysaccharide (MFPs-1-FITC) labeled with FITC is shown in Figure 1 As shown in (B), it coincides with the fluorescence absorption peak of FITC and Figure 1 In (C), MFPs-1-FITC exhibited a clear absorption peak at 490 nm, indicating that FITC was successfully labeled to the polysaccharide.
[0145] 1.4.2 Fluorescence spectroscopy of MFPs-1-FITC
[0146] FITC is an orange-yellow powder with a maximum light absorption wavelength of 490-485nm and a maximum emission wavelength of 520-530nm. Its water and ethanol solutions show bright yellow-green fluorescence. The freeze-dried form of MFPs-1-FITC is orange-yellow flocculent, and its aqueous solution is yellow-green. Fluorescence spectroscopy analysis shows that unlabeled MFPs-1 lacks characteristic excitation and emission wavelengths; while FITC has an excitation wavelength of λEx = 493nm and an emission wavelength of λEm = 521nm. The excitation wavelength of MFPs-1-FITC is λEx = 492nm and the emission wavelength is λEm = 518nm, indicating that FITC successfully labeled polysaccharides and that the spectral characteristics remain stable after labeling.
[0147] 1.4.3 Determination of fluorescence substitution degree of MFPs-1-FITC
[0148] In order to clarify the fluorescence labeling rate of FITC on MFPs-1, this experiment used a multifunctional microplate reader to detect the FITC substitution degree. First, FITC was dissolved in PBS solution at 0.1-2.0 μg mL -1 A standard curve was established within the range of 1.3 % and the linear regression equation was: y = 796.27x–83.677, R 2 =0.9966, good linearity ( Figure 2-4 ). The measured fluorescence intensity of MFPs-1-FITC was substituted into the standard curve for calculation, and the results showed that the average degree of substitution of FITC in MFPs-1-FITC was 1.28%.
[0149] 1.5 Conclusion
[0150] The study showed that UV and fluorescence spectroscopy analysis confirmed that FITC could bind to MFPs-1, and the degree of substitution of FITC in MFPs-1-FITC was 1.28%.
[0151] 2 Establishment of quantitative detection method of fluorescent labeled polysaccharides in biological samples
[0152] 2.1 Experimental Materials and Reagents
[0153] The fluorescent polysaccharide MFPs-1 was prepared according to the method in item “1.2.1”, and MFPs-1-FITC was prepared according to the method in item “1.2.2”.
[0154] 2.2 Experimental animals
[0155] Sprague-Dawley rats (SPF grade, weight ≤ 250 g, male) were provided by Changsha Tianqin Biotechnology Co., Ltd., license number SCXK (Xiang) 2022-0011. They were raised in the experimental animal room of Guizhou Normal University, and the environment was maintained at a relative humidity of 60% to 70% and a temperature of 20°C to 25°C to ensure their health and compliance with the ethical standards of animal experiments and the accuracy of the data obtained.
[0156] 2.2.1 Biological sample model preparation
[0157] Healthy male SD rats were divided into 4 groups, including two normal rats, one normal control group, another normal rat + MFPs-1-FITC group, and the other two groups were alcoholic liver injury model group and alcoholic liver injury model + MFPs-1-FITC group. Both the normal rat + MFPs-1-FITC group and the alcoholic liver injury model + MFPs-1-FITC group were given 150 mg / kg of MFPs-1-FITC by gavage. At the set time points (0.25h, 0.5h, 1h, 2h, 4h, 8h, 24h), blood and various tissue samples were collected, and the fluorescence intensity of MFPs-1-FITC in plasma and tissues was measured using a multifunctional microplate reader. Meanwhile, to evaluate the excretion, healthy rats were placed in metabolic cages and also given 150 mg / kg of MFPs-1-FITC, and urine and feces samples were collected at different time periods (0-1, 1-2, 2-4, 4-6, 6-8, 8-12, and 12-24 h), and the fluorescence intensity therein was measured after processing.
[0158] 2.3 Establishment of quantitative detection method of MFPs-1-FITC in biological samples
[0159] 2.3.1 Fluorescence measurement conditions
[0160] The fluorescence excitation wavelength Ex of MFPs-1-FITC is 492 nm, and the fluorescence emission wavelength Em is 518 nm. Its fluorescence intensity is measured under these conditions by a multifunctional microplate reader.
[0161] 2.3.2 Biological sample processing methods
[0162] (1) Plasma sample determination method: Take 120 μL of plasma, add 120 μL of phosphate buffered saline (PBS), vortex mix, centrifuge at 5000 r / min for 10 min, and take the supernatant to measure the fluorescence intensity under the above conditions.
[0163] (2) Tissue sample measurement method: Accurately weigh an appropriate amount of tissue sample, add 9 times the weight of the tissue in phosphate buffered saline (PBS), homogenize the tissue using a homogenizer, centrifuge at 12000 r / min for 10 min, and take the supernatant to measure the fluorescence intensity under the above conditions.
[0164] (3) Urine sample determination method: Take 40 μL of urine filtered through a microporous membrane, add 200 μL of phosphate buffered saline (PBS), vortex mix, centrifuge at 12000 r / min for 10 min, and take the supernatant to measure the fluorescence intensity under the above conditions.
[0165] (4) Determination method of fecal samples: Accurately weigh an appropriate amount of fecal sample that has been dried to constant weight, dilute with PBS solution (fecal sample: PBS = 1:9), vortex for 10 min, let stand for 10 min, centrifuge at 12000 r / min for 10 min, and take the supernatant to measure the fluorescence intensity under the above conditions.
[0166] 2.3.3 Drawing of standard curve
[0167] Preparation of standard curve: Accurately take 200 μL of rat heart tissue homogenate, add reference solution to prepare a series of solutions of different concentrations (0.3 to 30.0 μg / mL), and measure the fluorescence intensity. Use PBS as a blank control, with the mass concentration of MFPs-1-FITC as the X-axis and the fluorescence intensity as the Y-axis, draw a standard curve and obtain the regression equation. The standard curve drawing method for plasma, urine and feces samples is consistent with that for tissue samples.
[0168] 2.3.4 Accuracy and precision investigation
[0169] Preparation of reference solution: blank plasma, tissue homogenate supernatant, urine supernatant and feces supernatant of rats were taken respectively, and different concentrations of MFPs-1-FITC solution were added to prepare samples with final concentrations of high (30.0 μg / mL), medium (3.0 μg / mL) and low (0.3 μg / mL) as quality control samples (Quality control, QC). Three parallel samples were prepared for each concentration.
[0170] 2.3.5 Stability study
[0171] Take three quality control samples with high, medium and low concentrations, place them at room temperature for 24 hours and at -20℃ for 14 days respectively, measure the fluorescence intensity, substitute it into the standard curve to obtain the mass concentration of the samples, and calculate the recovery rate and RSD value.
[0172] 2.4 Data processing and statistical analysis
[0173] The experimental results were expressed as mean ± standard deviation. All data were statistically analyzed and plotted using Microsoft Excel and Origin2022 software.
[0174] 2.5 Results
[0175] 2.5.1 Standard curve
[0176] The standard curve was drawn using the concentration of MFPs-1-FITC in tissues, plasma, and excreta as the X-axis and the corresponding fluorescence intensity as the Y-axis. 2The values ranged from 0.9955 to 0.9998, indicating that MFPs-1-FITC was present in the range of 0.3 to 30 μg mL -1 There is a good linear relationship within the range. The linear range, regression equation and correlation coefficient are shown in Table 2, which meets the requirements of linear dynamics.
[0177] Table 2 Standard curve of MFPs-1-FITC in biological samples for oral administration
[0178]
[0179]
[0180] 2.5.2 Accuracy and precision of MFPs-1-FITC in biological samples
[0181] The intra-day precision and inter-day precision of MFPs-1-FITC in plasma, tissues and excreta are shown in Table 3. Three samples were measured for each concentration. Accuracy and precision were expressed as relative error (RE, %) and relative standard deviation (RSD, %), respectively. Accuracy, intra-day precision and inter-day precision were -2.04% to 9.77%, 0.10% to 12.36%, and 0.91% to 10.94%, respectively, which all met the requirements for biological sample determination. The results showed that this method has high accuracy and precision, and the plasma and tissue matrix effects have no effect on the determination of drug concentration.
[0182] Table 3 Accuracy and precision of MFPs-1-FITC in biological samples (n=3)
[0183]
[0184]
[0185] 2.5.3 Stability of MFPs-1-FITC in biological samples
[0186] The stability test results (see Table 4) evaluated the stability of the samples at room temperature and frozen at -20°C. Three samples were tested at each concentration level by comparing the measurement results under the two conditions. The data showed that the recovery of MFPs-1-FITC was between 94.13% and 114.15%, and the RSD values were all lower than 14.99%, which confirmed that MFPs-1-FITC exhibited stable quality at room temperature and -20°C. Good stability means that the sample can maintain its characteristics within the predetermined validity period, thereby ensuring the validity of the measurement and analysis results based on these samples.
[0187] Table 4 Stability of MFPs-1-FITC for oral administration in biological samples (n=3)
[0188]
[0189]
[0190] 2.5 Conclusion
[0191] MFPs-1-FITC has a good linear relationship in three biological samples: plasma, tissues and organs, and excreta. 2 The range of the accuracy, inter-day precision and intra-day precision of MFPs-1-FITC in three biological samples was -2.04% to 9.77%, 0.10% to 12.36%, and 0.91% to 10.94%, respectively. The recovery of MFPs-1-FITC at room temperature for 24 hours was between 96.95% and 111.93%, and the precision was between 0.28% and 14.99%; the recovery of MFPs-1-FITC stored in a -20℃ refrigerator for 30 days was between 97.07% and 108.85%, and the precision was between 0.01% and 5.68%.
[0192] Pharmacokinetics of 3MFPs-1-FITC after oral administration
[0193] 3.1 Experimental animals
[0194] Male Sprague-Dawley rats (SPF grade, weight ≤ 250 g) were supplied by Changsha Tianqin Biotechnology Co., Ltd., license SCXK (Xiang) 2022-0011. They were raised in the experimental animal room of Guizhou Normal University, and the environment was maintained at a relative humidity of 60% to 70% and a temperature range of 20°C to 25°C.
[0195] 3.2 Experimental methods
[0196] 3.2.1 Establishment of rat model of alcoholic liver injury
[0197] (1) Grouping of rats
[0198] 84 healthy male SD rats were raised in a standard experimental environment with adequate feed and free access to water and food. The animal room was kept clean and well ventilated during the experiment. After 3 days of adaptive feeding, the 84 healthy male SD rats were randomly divided into 4 groups: Group 1 was a blank group, Group 2 was "normal rats + MFPs-1-FITC (150 mg / kg)", Group 3 was "alcoholic liver injury model rats", and Group 4 was "alcoholic liver injury model rats + MFPs-1-FITC (150 mg / kg)", with 21 rats in each group. The rats were marked at the tail with a marker pen and weighed for modeling.
[0199] (2) Rat modeling
[0200] All rats were gavaged for modeling. The gavage volume of normal saline and 56-degree liquor was 0.01 mL / g, and the modeling time was 7 days. The specific operation was as follows; Group 1 and Group 2: According to the weight of the rats, gavage 0.01 mL / g of normal saline once a day for 7 consecutive days. Group 3 and Group 4: According to the weight of the rats, gavage 0.01 mL / g of 56-degree liquor once a day for 7 consecutive days. Ensure that the gavage time of rats in the experiment is synchronized, and check the physiological condition within 1 hour after gavage, deal with the dead individuals in time, and maintain sufficient feed and fresh drinking water. After gavage on the 7th day, fasting but not water for 12 hours, weighing the body weight, and conducting the next experiment.
[0201] 3.2.2 Study on blood concentration and tissue distribution of MFPs-1-FITC after oral administration
[0202] On the 8th day of the experiment, MFPs-1-FITC (150 mg / kg) was gavaged according to the body weight of rats in groups 2 and 4, and the corresponding volume of saline was gavaged in groups 1 and 3. Blood was collected from the orbit at 0.25, 0.5, 1, 2, 4, 8, and 24 h after administration, and blood samples were collected in anticoagulant tubes wrapped in tin foil. After the blood samples were collected, the rats were dissected immediately, and samples of heart, liver, spleen, lung, kidney, stomach, large intestine, small intestine, and brain tissue were collected, washed with saline, dried with filter paper, accurately weighed, and stored at -80°C until analysis.
[0203] The collected blood samples were immediately heated at 4°C, 4000 r min -1 Centrifuge for 15 min under the same conditions and collect the separated plasma samples. Take 120 μL of plasma sample, add 120 μL of PBS solution, vortex mix, and centrifuge at 4000 r min. -1 After centrifugation for 15 min, the supernatant was collected and the fluorescence intensity of the plasma sample was measured using a multifunctional microplate reader at λex: 492 nm, λem: 518 nm. The measured fluorescence intensity was substituted into the standard curve to calculate the drug concentration.
[0204] The collected tissue samples were added with 9 times the volume of PBS solution of the organ weight and homogenized with a homogenizer at 12000r min. -1 Centrifuge for 10 minutes, take the supernatant, and use a multifunctional microplate reader to measure the fluorescence intensity of the tissue sample under the conditions of λex: 492nm, λem: 518nm. Substitute the measured fluorescence intensity into the standard curve to calculate the drug concentration in the tissue.
[0205] 3.2.3 Excretion study of MFPs-1-FITC after oral administration
[0206] Rats fasted overnight received 150 mg / kg MFPs-1-FITC by oral gavage according to body weight and were then placed in metabolic cages to collect urine and feces samples at different time periods (0-1h, 1-2h, 2-4h, 4-6h, 6-8h, 8-12h, 12-24h).
[0207] Urine samples were collected at 4000 r min -1 The supernatant was collected and filtered through a 0.45 μm filter membrane and placed in an EP tube and stored in a -80°C refrigerator for later use. The fecal samples were dried to constant weight, weighed, and stored at -80°C until analysis.
[0208] Take 40 μL of urine filtered through a microporous membrane, add 200 μL of PBS, vortex mix, and spin at 12000 r min. -1 After centrifugation for 10 min, the supernatant was collected and the fluorescence intensity of the tissue sample was measured using a multifunctional microplate reader at λex: 492 nm, λem: 518 nm. The measured fluorescence intensity was substituted into the standard curve to calculate the drug concentration in urine.
[0209] Take the dried feces sample, add 9 times the volume of PBS solution, vortex for 10 minutes, let it stand for 10 minutes, and rotate at 12000 rpm. -1 , centrifuge for 10 minutes, take the supernatant, and use a multifunctional microplate reader to measure the fluorescence intensity of the tissue sample under the conditions of λex: 492nm, λem: 518nm. Substitute the measured fluorescence intensity into the standard curve to calculate the drug concentration in the feces.
[0210] 3.3 Statistical analysis of data
[0211] All data were statistically processed and plotted using Microsoft Excel and origin 2022 software. DAS2.0 software was used to calculate relevant pharmacokinetic parameters, and the data values were expressed as mean ± standard deviation ( ). The t-test was used to evaluate the statistical significance between different groups, and P < 0.05 was considered statistically significant.
[0212] 3.4 Results
[0213] 3.4.1 Blood concentration-time curve of MFPs-1-FITC after oral administration
[0214] Rats in the normal group and the alcoholic liver injury model group were intragastrically administered with 150 mg kg -1 After adding MFPs-1-FITC, the measured plasma drug concentration and the corresponding time point were plotted. The plasma drug concentration-time curve is shown in Figure 3The results showed that after intragastric administration of MFPs-1-FITC, the plasma MFPs-1-FITC concentration in the normal group rats gradually increased with time and reached a peak at 0.5h. max The concentration of MFPs-1-FITC in the plasma of rats in the model group gradually increased and reached a peak at 0.5h. max It was 2.06μg / mL, and then gradually decreased, similar to that of the normal group rats.
[0215] 3.4.2 Pharmacokinetics of MFPs-1-FITC after oral administration
[0216] The pharmacokinetic parameters of MFPs-1-FITC were calculated using DAS2.0 pharmacokinetic software, as shown in Table 5. The results showed that the metabolism of MFPs-1-FITC in rats followed a two-compartment model, and the fitting constant R 2 >0.99. Table 5 shows that the half-life of MFPs-1-FITC in the two groups of rats (t 1 / 2 ) were 19.43±5.78h and 31.01±0.54h, respectively. The area under the plasma level-time curve (AUC 0→24h ) were 32.22±4.91mg h / L and 9.79±0.02mg h / L respectively. The AUC 0→∞ ) were 7.96±4.39mg h / L and 31.34±0.54mg h / L, respectively. The CL / F values were 20.51±4.97L / h / kg and 6.42±1.58L / h / kg, respectively. The CL / F value is an indicator for estimating the elimination rate of samples in vivo. The ratio (V / F) of the apparent distribution volume (V) to the bioavailability (F) of the two groups of rats was 14.48±8.71L / kg and 14.17±1.55L / kg, respectively. In rats, the blood concentration of MFPs-1-FITC quickly reached a peak at 0.5h and showed a long biological half-life (normal group t 1 / 2 The model group had a t 1 / 2 31.01±0.54h), indicating that MFPs-1-FITC is absorbed quickly and eliminated slowly in the body, which may be related to the macromolecular characteristics of polysaccharides.
[0217] Table 5 Pharmacokinetic parameters of rats in the normal group and model group after administration of MFPs-1-FITC
[0218]
[0219]
[0220] 3.4.3 Tissue distribution study of MFPs-1-FITC after oral administration
[0221] The tissue distribution of rats in the normal group and model group after oral administration of 150 mg / kg MFPs-1-FITC is shown in Tables 6 and 7. The results showed that MFPs-1-FITC was mainly distributed in the stomach, large intestine and small intestine, followed by the liver, and relatively less in the spleen, lung and kidney, regardless of whether it was the normal group or the model group. After oral administration, MFPs-1-FITC was not detected in the heart and brain of the two groups of rats, indicating that MFPs-1 is difficult to pass through the blood-brain barrier to reach the brain. MFPs-1-FITC can be detected in the stomach 15 minutes after administration, and the concentration gradually decreases with time, while the MFPs-1-FITC content in the large intestine continues to increase, reaching a peak at 2 hours, and then slowly decreases. MFPs-1-FITC was not detected in the kidneys of rats in the normal group and the model group at 0.25h, 0.5h and 1h. MFPs-1-FITC began to be detected at 2h and reached a peak at 4h. Then the content began to decrease, but MFPs-1-FITC could still be detected at 24h. MFPs-1-FITC in the liver of rats in the normal group reached a peak at 4h, while MFPs-1-FITC in the liver of rats in the model group reached a peak at 8h. MFPs-1-FITC in the small intestine of both groups of rats reached a peak at 1h. Oral administration is a common route of administration for drugs, including traditional Chinese medicine, due to its convenience and recognized safety record. For various reasons, oral administration is mainly absorbed in the small intestine. The small intestine has a large absorption surface area, large blood flow, and long drug retention time. Small molecule drugs are mainly absorbed through simple diffusion processes, but macromolecular drugs such as peptides and nanoparticles may rely on endocytosis mechanisms, including clathrin-mediated endocytosis, vesicle-mediated endocytosis, microprotein endocytosis, and phagocytosis. As macromolecular substances, polysaccharides may be absorbed by a similar mechanism as peptides and nanoparticles. 24 hours after administration, MFPs-1-FITC can be detected in all tissues tested except the heart and brain, with the highest content in the liver. The liver is the largest internal organ in the human body and the main site of metabolism of endogenous molecules and exogenous drugs. Its first-pass metabolism and efflux processes will further reduce the oral bioavailability of drugs.
[0222] Table 6 Tissue distribution of MFPs-1-FITC at different time points after oral administration to normal rats
[0223]
[0224] Compare, d P<0.05; compared with 4h, e P<0.05; compared with 8h, f P<0.05.
[0225] Table 7 Tissue distribution of MFPs-1-ANTS at different time points after oral administration in rats with alcoholic liver injury model
[0226]
[0227] Note: Compared with 0.25h, a P<0.05; compared with 0.5h, b P<0.05; compared with 1h, c P<0.05; compared with 2h, d P<0.05; compared with 4h, e P<0.05; compared with 8h, f P<0.05.
[0228] 3.4.4 Excretion study of MFPs-1-FITC after oral administration
[0229] The MFPs-1-FITC concentration in rat urine and feces was measured using a multifunctional microplate reader, and the cumulative excretion and its percentage of the administered dose were calculated. After a single dose of 150 mg / kg MFPs-1-FITC, the average cumulative excretion in urine and feces within 0-24 hours and its percentage are shown in Figure 2. Figure 4 , Figure 5 shown. Figure 4 It shows that the excretion rate is faster within 0-12 hours after administration, and the excretion rate is relatively stable during 12-24 hours. Figure 5 The results showed that the cumulative excretion of MFPs-1-FITC in urine within 24 hours accounted for 1.45% of the administered dose, and the cumulative excretion in feces accounted for 2.44% of the administered dose.
[0230] 3.5 Conclusion
[0231] This chapter uses the fluorescence quantitative analysis method in biological samples established in the previous chapter to study the pharmacokinetic characteristics of MFPs-1-FITC in normal rats and rats with alcoholic liver injury model after oral administration. The main conclusions are as follows:
[0232] (1) After a single oral administration of MFPs-1-FITC, MFPs-1-FITC could be detected in the plasma of both the normal group and the model group at 0.25 h, and reached a peak at 0.5 h. Thereafter, its concentration gradually decreased at a slower rate over time.
[0233] (2) DAS2.0 software was used for intelligent analysis. The results showed that the metabolism of MFPs-1-FITC in normal rats and rats with alcoholic liver injury followed a two-compartment model, with an elimination half-life of t 1 / 2The elimination rate of the model group was lower than that of the normal group.
[0234] (3) MFPs-1 is widely distributed in tissues in the body, with the highest distribution in the gastrointestinal tract, followed by the liver, and less in the spleen, lung, and kidney. It cannot pass through the blood-brain barrier.
[0235] (4) Within 24 hours after oral administration, MFPs-1-FITC will be excreted in urine and feces, with fecal excretion being the main excretion route.
[0236] (5) In summary, after oral administration, MFPs-1 can be absorbed through the stomach and intestines, then enter the liver, and finally excreted through urine and feces. In addition, we also found that when normal rats and rats with alcoholic liver injury model were given the same dose of MFPs-1-FITC, the MFPs-1-FITC content in the liver of the two groups of rats was different. The MFPs-1-FITC content in the liver of normal rats reached a peak at 4 hours, while the MFPs-1-FITC in the liver of rats in the alcoholic liver injury model group reached a peak at 8 hours, and the concentration was higher than that of MFPs-1-FITC in the liver of normal rats. The liver is the first barrier for the absorption of exogenous substances. The concentration of MFPs-1-FITC in the liver reflects the absorption level of MFPs-1-FITC. Compared with the plasma concentration, the concentration of MFPs-1-FITC in the liver increased significantly and lasted for a long time, indicating that MFPs-1-FITC can be absorbed by the circulatory system, indicating that MFPs-1 has a certain protective effect on the liver. In addition, MFPs-1-FITC stays in the intestine for a long time, indicating that MFPs-1 also has a certain therapeutic effect on intestinal diseases.
Claims
1. A fluorescent labeling product MFPs-1-FITC for treating alcoholic liver damage, Features: The fluorescent labeling product MFPs-1-FITC is obtained by first separating and purifying mulberry fruit to obtain fluorescent polysaccharide MFPs-1, synthesizing fluorescent polysaccharide MFPs-1 with 4-hydroxyphenylethylamine to obtain MFPs-1-Tyr, and then synthesizing MFPs-1-Tyr with fluorescein isothiocyanate.
2. The method for preparing the fluorescent labeled product MFPs-1-FITC for treating alcoholic liver injury according to claim 1, Features: The preparation method is carried out according to the following steps: (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 30-60 mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1g:2-4mL, each time for 1.5-2.5h, defatting 2-4 times, discarding the petroleum ether layer, obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 80-100°C, the ratio of mulberry sample to distilled water is 1g:2-4mL, each time for 1.5-2.5h, extracting 2-4 times, filtering, combining the filtrate, centrifuging the filtrate at 3500rpm for 5-15min, concentrating the supernatant, and obtaining a mulberry polysaccharide extract; (2) adding 2.5%-3.5% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution is 0.5-1.5:0.5-1.5, standing at 4°C for 3-5 hours, centrifuging at 3000-4000 r / min for 5-15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 2.5%-3.5% trichloroacetic acid solution, the mass ratio of the concentrate to 3% trichloroacetic acid solution is 0.5-1.5:0.5-1.5, standing at 4°C for 3-5 hours, centrifuging at 3000-4000 r / min for 5-15 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution; (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 40-60%, placing the solution at 3-5°C for 22-26 hours, centrifuging at 3500 r / min for 5-15 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP; (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 200-400 mL of distilled water, collect 20-40 tubes of eluate, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, concentrate, dialyze the concentrate with a 3500Da dialysis bag, and vacuum freeze-dry the dialyzate to obtain the fluorescent polysaccharide MFPs-1; (5) Synthesis of MFPs-1-Tyr: 300-500 mg of fluorescent polysaccharide MFPs-1 was dissolved in 10-20 mL of 0.2 mol / L phosphate buffer at pH 8.0, 300-500 mg of Tyr and 100.00-200.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 90-100 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex Elution was performed through a G-100 column with 200-400 mL of distilled water, and 20-40 tubes of eluate were collected, with 10 mL in each tube. The sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry. The eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined, dialyzed with a 3500 Da dialysis bag, and freeze-dried to obtain MFPs-1-Tyr; (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water and 0.5 mol / L Na 2 CO 3 The pH value was adjusted to 8-9, 40-60 mg of fluorescein isothiocyanate was added, and the mixture was reacted in the dark for 10-14 hours at room temperature, and then 2-4 times the volume of anhydrous ethanol was added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved with water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500Da dialysis bag, and the dialysate was eluted and purified through a Sephadex G-100 column, eluted with 200-400 mL of distilled water, 20-40 tubes of eluate were collected, each tube had 10 mL, and the sugar content was determined by the phenol-sulfuric acid method, and the sugar-containing eluate was taken, and the fluorescence intensity was determined by fluorescence spectral analysis, with an excitation wavelength of 492 nm and an emission wavelength of 518 nm; the eluate with fluorescence absorption at 490 nm was collected, combined, and freeze-dried to obtain a fluorescent labeled product MFPs-1-FITC, and stored in the dark.
3. The preparation method according to claim 2, Features: The preparation method is carried out according to the following steps: (1) Dry mulberry fruit and dry it to constant weight, grind it into powder with a grinder, pass it through a 40-mesh sieve, extract and defatted it with petroleum ether, the ratio of mulberry fruit to petroleum ether is 1 g:3 mL, each time for 2 hours, defatting 3 times, discarding the petroleum ether layer, obtaining a defatted mulberry sample, extracting the defatted mulberry sample with distilled water at 90° C., the ratio of mulberry sample to distilled water is 1 g:3 mL, each time for 2 hours, extracting 3 times, filtering, combining the filtrate, centrifuging the filtrate at 3500 rpm for 10 minutes, and concentrating the supernatant to obtain a mulberry polysaccharide extract; (2) adding 3% trichloroacetic acid solution to mulberry polysaccharide extract, the mass ratio of mulberry polysaccharide extract to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, taking the concentrate and adding 3% trichloroacetic acid solution, the mass ratio of mulberry concentrate to 3% trichloroacetic acid solution being 1:1, standing at 4°C for 4 hours, centrifuging at 3500 r / min for 10 minutes, collecting the supernatant, concentrating the supernatant with a rotary evaporator, and obtaining a deproteinized mulberry polysaccharide solution; (3) adding anhydrous ethanol to the deproteinized mulberry polysaccharide solution until the ethanol concentration in the solution reaches 50%, placing it at 4°C for 24 hours, centrifuging it at 3500 r / min for 10 minutes, collecting the precipitate, washing the precipitate three times with anhydrous ethanol, and vacuum freeze-drying to obtain mulberry polysaccharide MFP; (4) Purify the mulberry polysaccharide MFP using a DEAE-52 cellulose column, elute with 300 mL of distilled water, collect 30 tubes of eluate, collect 10 mL of eluate in each tube, and use the phenol-sulfuric acid method to track and determine the sugar content of each tube of eluate until there is no polysaccharide, collect the sugar-containing eluate with an absorption peak at 490 nm, combine, and concentrate. The concentrate is dialyzed with a 3500Da dialysis bag, and the dialyzate is vacuum freeze-dried to obtain the fluorescent polysaccharide MFPs-1; (5) Synthesis of MFPs-1-Tyr: 400 mg of fluorescent polysaccharide MFPs-1 was dissolved in 15 mL of 0.2 mol / L phosphate buffer at pH 8.0, 400 mg of Tyr and 150.00 mg of sodium cyanoborohydride were added, and the mixture was reacted in a 37°C water bath for 96 h. After the reaction was completed, the mixture was centrifuged and the supernatant was dialyzed using a 3500 Da dialysis bag. The dialyzate was filtered through Sephadex. Elution was performed through a G-100 column with 300 mL of distilled water, and 30 tubes of eluate were collected, with 10 mL in each tube; the sugar content in each tube was determined by the phenol-sulfuric acid method, and the eluate determined to contain sugar was used to draw the elution curve of MFPs-1-Tyr at 280 nm by UV-visible spectrophotometry, and the eluate with UV absorption at 280 nm was collected according to the elution curve, and the eluate was combined, dialyzed with a 3500 Da dialysis bag, and freeze-dried to obtain MFPs-1-Tyr; (6) Synthesis of MFPs-1-FITC: The MFPs-1-Tyr obtained in step (5) was dissolved in distilled water and 0.5 mol / L Na 2 CO 3 The pH value was adjusted to 8.5, 50 mg of fluorescein isothiocyanate was added, and the mixture was reacted at room temperature in the dark for 12 hours, and then 3 times the volume of anhydrous ethanol was added to produce a yellow-green precipitate; the precipitate was separated by centrifugation, the precipitate was redissolved in water, and then precipitated with anhydrous ethanol, and the redissolution-precipitation process was repeated three times; after the precipitate was dissolved, it was dialyzed with a 3500Da dialysis bag, and the dialysate was eluted and purified through a Sephadex G-100 column, eluted with 300 mL of distilled water, and 30 tubes of eluate were collected, each tube having 10 mL; the sugar content was determined by the phenol-sulfuric acid method, the sugar-containing eluate was collected, and the fluorescence intensity was determined by fluorescence spectral analysis, with an excitation wavelength of 492 nm and an emission wavelength of 518 nm, the eluate with fluorescence absorption at 490 nm was collected, and freeze-dried to obtain the fluorescent labeled product MFPs-1-FITC, which was stored in the dark.
4. Use of the fluorescent labeled product MFPs-1-FITC for treating alcoholic liver damage as claimed in claim 1 in biological detection, Features: The biological detection method of the fluorescent labeled product MFPs-1-FITC is carried out according to the following steps: (1) diluting MFPs-1-FITC with water to prepare a 100-200 mg / kg MFPs-1-FITC solution, and administering the MFPs-1-FITC solution to rats by intragastric administration, with the intragastric dose being 100-200 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample; (2) Preparation of plasma samples: blood was collected from the orbits of rat biological samples and collected into anticoagulant tubes. The blood samples were centrifuged at 3000-5000 r / min for 5-15 min at 3-5°C to separate the plasma. 100-150 μL of plasma was taken, 100-150 μL of PBS solution was added, vortexed and mixed, and centrifuged at 4000-6000 r / min for 5-15 min to obtain the supernatant to obtain the plasma sample. (3) Preparation of tissue samples: Collect rat biological sample organ tissues, wash with physiological saline and dry the surface moisture, accurately weigh the organ tissues, add PBS solution, the mass ratio of organ tissue to PBS solution is 1:8-10, use a homogenizer to homogenize the tissues, centrifuge at 10000-14000 r / min for 5-15 min, take the supernatant and obtain the tissue sample; The rat organ tissues include stomach, large intestine, small intestine, liver, spleen, lung and kidney; (4) Preparation of urine samples: Take rat biological sample urine, centrifuge at 3000-5000 r / min for 5-15 min, filter and take 30-50 μL of supernatant, filter through a microporous filter, add 150-250 μL of PBS solution, vortex mix, centrifuge at 10000-14000 r / min for 5-15 min, take the supernatant, and obtain a urine sample; (5) Preparation of fecal samples: Rat biological sample feces was dried to constant weight, and then added with PBS solution, with the mass ratio of feces to PBS solution being 1:8-10. After mixing, the mixture was vortexed for 5-15 min, allowed to stand for 5-15 min, and centrifuged at 10000-14000 r / min for 5-15 min. The supernatant was collected to obtain a fecal sample. (6) Fluorescence intensity detection: Plasma samples, tissue samples, urine samples and feces samples were taken separately, and PBS solution was used as a blank control for fluorescence intensity detection. The fluorescence excitation wavelength Ex was 492 nm, and the fluorescence emission wavelength Em was 518 nm. The instrument was a multifunctional microplate reader. The measured fluorescence intensity of each sample was subtracted from the measured fluorescence intensity of the blank control to obtain the actual fluorescence intensity of each sample.
5. The use according to claim 4, Features: In the step (1), MFPs-1-FITC is diluted with water to prepare a 150 mg / kg MFPs-1-FITC solution, and the MFPs-1-FITC solution is administered to rats by intragastric administration, with the intragastric dose being 150 mg of MFPs-1-FITC per kg of rat, to obtain a rat biological sample.
6. The use according to claim 4, Features: In the step (2), the preparation of the plasma sample is as follows: blood is collected from the eye sockets of the rat biological sample, the blood sample is collected in an anticoagulant tube, and the blood is centrifuged at 4000 r / min for 10 min at 4°C to separate the plasma, 120 μL of plasma is taken, 120 μL of PBS solution is added, the mixture is vortexed and mixed, and the mixture is centrifuged at 5000 r / min for 10 min to take the supernatant to obtain a plasma sample.
7. The use according to claim 4, Features: In the step (3), the tissue sample is prepared by collecting rat biological sample organ tissue, washing it with physiological saline and drying the surface moisture, accurately weighing the organ tissue, adding PBS solution, the mass ratio of the organ tissue to the PBS solution is 1:9, homogenizing the tissue with a homogenizer, centrifuging at 12000r / min for 10min, taking the supernatant, and obtaining the tissue sample; The rat organ tissues include stomach, large intestine, small intestine, liver, spleen, lung and kidney.
8. The use according to claim 4, Features: In the step (4), the urine sample is prepared by taking rat biological sample urine, centrifuging at 4000 r / min for 10 min, filtering and taking 40 μL of supernatant, filtering with a microporous filter membrane, adding 200 μL of PBS solution, vortex mixing, centrifuging at 12000 r / min for 10 min, taking the supernatant, and obtaining a urine sample.
9. The use according to claim 4, Features: In the step (5), the feces sample is prepared by drying the feces of the rat biological sample to a constant weight, adding a PBS solution, the mass ratio of feces to PBS solution being 1:9, mixing, vortexing for 10 minutes, standing for 10 minutes, centrifuging at 12000 r / min for 10 minutes, and taking the supernatant to obtain a feces sample.
10. The use according to claim 4, Features: In the step (6), the fluorescence intensity of the stool sample is obtained by subtracting the fluorescence intensity of the blank control from the fluorescence intensity of the stool sample.
Citation Information
Cited By
Dendrobium officinale polysaccharide responsive fluorescent marker with high optical stability and preparation method thereof
CN116375899A
